0001209191-20-052021.txt : 20200924
0001209191-20-052021.hdr.sgml : 20200924
20200924192950
ACCESSION NUMBER: 0001209191-20-052021
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200924
FILED AS OF DATE: 20200924
DATE AS OF CHANGE: 20200924
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scherle Peggy
CENTRAL INDEX KEY: 0001824632
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39527
FILM NUMBER: 201196508
MAIL ADDRESS:
STREET 1: C/O PRELUDE THERAPEUTICS INCORPORATED
STREET 2: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prelude Therapeutics Inc
CENTRAL INDEX KEY: 0001678660
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811384762
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: (302) 547-3768
MAIL ADDRESS:
STREET 1: 200 POWDER MILL ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: Prelude Therapeutics Inc.
DATE OF NAME CHANGE: 20160630
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-09-24
0
0001678660
Prelude Therapeutics Inc
PRLD
0001824632
Scherle Peggy
C/O PRELUDE THERAPEUTICS INCORPORATED
200 POWDER MILL ROAD
WILMINGTON
DE
19801
0
1
0
0
Chief Scientific Officer
Common Stock
172920
D
Employee Stock Option (right to buy)
1.43
2028-11-12
Common Stock
86460
D
Employee Stock Option (right to buy)
1.43
2029-02-12
Common Stock
43230
D
Employee Stock Option (right to buy)
1.89
2030-03-26
Common Stock
43230
D
Employee Stock Option (right to buy)
12.85
2030-09-01
Common Stock
185888
D
Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
The stock option vested as to 25% of the total shares on November 13, 2019, and thereafter vests as to 1/48 on the first day of each month for 36 months until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The stock option vested as to 25% of the total shares on February 13, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The stock option vests as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The stock option vests as to 25% of the total shares on September 24, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Brian Piper, as Attorney-in-Fact for Peggy Scherle
2020-09-24
EX-24.3_938659
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints Brian Piper and Krishna Vaddi and each of them, as his true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as a representative of Prelude Therapeutics Incorporated (the "Company"), any
and all Form ID, or Form 3, 4 or 5 reports and any amendments thereto required
to be filed by the undersigned in accordance with Section 16(a) of the
Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder
with respect to transactions in the Company's securities;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form ID, or Form
3, 4 or 5 report and any amendments thereto and timely file such report with the
U.S. Securities and Exchange Commission and any stock exchange or similar
authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney in-fact may approve in his or
her discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary, and proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or his or her
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this Power of Attorney and the rights and powers herein granted. The
undersigned acknowledges that no such attorney in-fact, in serving in such
capacity at the request of the undersigned, is hereby assuming, nor is the
Company hereby assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
The undersigned agrees that each such attorney-in-fact may rely entirely on
information furnished orally or in writing by the undersigned to each such
attorney-in-fact. The undersigned also agrees to indemnify and hold harmless
the Company and each such attorney-in-fact against any losses, claims, damages
or liabilities (or actions in these respects) that arise out of or are based on
any untrue statement or omission of necessary facts in the information provided
by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing Forms 3, 4 or 5 (including amendments
thereto) and agrees to reimburse the Company and each such attorney-in-fact for
any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss, claim, damage, liability or action.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Form 3, 4 or 5 reports with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 2nd day of September, 2020.
/s/ Peggy Scherle